Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11886853 | 0.82 | AKR1B1 (0.47) | GAAALDH1A1KMT2A | |
| SCHEMBL21625361 | 0.82 | RXRA (0.39) | GAAALDH1A1NPC1TP53GLA | |
| SCHEMBL7143699 | 0.78 | SMN1; SMN2 (0.42) | GAAALDH1A1KMT2A | |
| SCHEMBL12737809 | 0.78 | ALDH1A1 (0.42) | GAAALDH1A1GLAKCNH2 | |
| SCHEMBL5172725 | 0.77 | AKR1B1 (0.38) | GAAALDH1A1KMT2A | |
| SCHEMBL25871760 | 0.77 | SMN1; SMN2 (0.45) | GAAALDH1A1GLAKMT2AKCNH2 | |
| SCHEMBL7144622 | 0.75 | ITGB2 (0.39) | GAALMNAKMT2A | |
| SCHEMBL3424828 | 0.75 | ITGB2 (0.39) | GAALMNAKMT2A | |
| SCHEMBL10284783 | 0.75 | ALDH1A1 (0.40) | GAAALDH1A1GLAKMT2AKCNH2 | |
| SCHEMBL17922547 | 0.74 | SIGMAR1 (0.40) | ALDH1A1SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101160305-A | Substituted chroman derivatives, method for the production and the use thereof in the form of antiphlogistics | SCHERING AG (DE) | 2008-04-09 | — | — | CN | disclosed |
| CN-101087780-A | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | BAYER SCHERING PHARMA AG (DE) | 2007-12-12 | — | — | CN | disclosed |
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| US-20060167025-A1 | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | SCHERING AG (DE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167025-A1 | Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs | ALDH7A1, NOTUM, GOT2 | GAA 3567/4885ALDH1A1 62/4885LMNA 4456/4885 |
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | GAA 1319/4885ALDH1A1 1563/4885LMNA 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.